Use of azathioprine for non-thymoma myasthenia and risk of cancer: A nationwide case-control study in Denmark

European Journal of Neurology

Volumn 20, Issue 6, 2013, Pages 942-948

  Pedersen, E G ^a   Pottegard A ^b   Hallas, J ^b   Friis, S ^c   Hansen, K ^d   Jensen, P E H ^d   Gaist, D ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Adverse effects; Cancer; Case control study; Epidemiology; Management; Medication; Myasthenia; Neurological disorders; Neuromuscular diseases; Research methods

Indexed keywords

AZATHIOPRINE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AZATHIOPRINE; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEOPLASMS; REGISTRIES; RISK FACTORS; THYMOMA; THYMUS NEOPLASMS;

EID: 84877654423     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12108     Document Type: Article

References (33)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
2. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
3. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008; 8: 87-93.
4. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(2 Suppl): S254-S264.
5. IARC. A Review of Human Carcinogens. Part A: Pharmaceuticals, Vol. 100A. Lyon: International Agency for Research on Cancer, 2008: 319-331.
6. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105: 1604-1609.
7. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2146-2153.
8. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001; 27: 750-756.
9. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
10. Citterio A, Beghi E, Millul A, et al. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009; 256: 1221-1227.
11. Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? Ann Neurol 2000; 47: 682-683.
12. Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237: 39-43.
13. Rawoot A, Little F, Heckmann JM. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years. S Afr Med J 2006; 96: 1249-1251.
14. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Identifying patients with myasthenia for epidemiological research by linkage of automated registers. Neuroepidemiology 2011; 37: 120-128.
15. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol 2012; 20: 309-314.
16. Gaist D, Andersen L, Hallas J, Toft Sørensen H, Schrøder HD, Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer 2013; doi: 10.1038/bjc.2012.536.
17. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(7 Suppl): 22-25.
18. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7 Suppl): 30-33.
19. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
20. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (DDDs). Oslo, Norway: WHO, 2000.
21. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39(7 Suppl): 42-45.
22. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010; 2: 51-56.
23. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams and Wilkins, 2008: 124-125.
24. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56: 645-646.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
26. Secretan B, Straif K, Baan R, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033-1034.
27. Owe JF, Dalveit AK, Gilhus NE. Does myasthenia gravis provide protection against cancer? Acta Neurol Scand Suppl 2006; 183: 33-36.
28. Liu CJ, Chang YS, Teng CJ, et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 2012; 19: 746-751.
29. Evoli A, Batocchi AP, Tonali P, Marciano M. Risk of cancer in patients with myasthenia gravis. Ann N Y Acad Sci 1998; 841: 742-745.
30. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol 2008; 15: 1029-1033.
31. Evoli A, Punzi C, Marsili F, et al. Extrathymic malignancies in patients with thymoma. Ann Oncol 2004; 290: 692-693.
32. Owe JF, Cvancarova M, Romi F, Gilhus NE. Extrathymic malignancies in thymoma patients with and without myasthenia gravis. J Neurol Sci 2009; 290: 66-69.
33. Engel PH, Sabroe S. Thymoma in Denmark. Ugeskr Laeger 1996; 159: 3156-3159. [In Danish].